Chercheur dans l'institut de recherche contre le cancer

Supported projects

The cluster provides access to the best oncology skills, tools, and services for the most promising projects led by organizations of varying sizes and maturity. The PSCC takes a selective approach, focusing its resources where they can have the greatest impact. We evaluate projects at different stages of maturity based on the quality of their team, scientific strength, development opportunities, and their alignment with the cluster's objectives. Our rigorous selection process involves an independent evaluation committee composed of experienced scientists and industry leaders.

Supported projects

They were accompanied

Apply with your project

Projects filters

Based on the discovery of the role of the transmembrane receptor Tmem176b in the regulation of tumour inflammation. It is developing compounds targeting this receptor to reactivate inflammation and boost anti-tumour activity, particularly in melanoma, colorectal cancer and chronic lymphatic leukaemia.

Argentina

Santa Fe

Biotech

Immunotherapy

Biotech - Lead optimization

ARDAN Pharma

Abcely is developing an innovative immunotherapy based on orally administered IgA monoclonal antibodies, targeting cancers of the digestive mucosa and endometriosis. Thanks to their polymeric structure, IgA antibodies are more avid for their target and recruit neutrophils more effectively. A unique platform for the identification, optimisation and production of these antibodies, offering an alternative to intravenous or subcutaneous IgG treatments.

France

Pays de la Loire

Biotech

Immunotherapy

Biotech - Pre-IND/Pre-CTA

Lauréat

iLAB

Abcely

Specializes in the discovery of biomarkers and the development of innovative medical diagnostics for precision medicine. In particular, it is developing GEMCITEST®, a blood test that predicts patient response to gemcitabine as a first-line treatment.

France

Occitanie

Medtech

DM/DiV

Medtech - Approval

Acobiom

Is developing a portfolio of first-in-class peptides targeting the tumour microenvironment. Its most advanced programme, AP-01, is a cyclic peptide inhibiting TSP-1, a ligand of the CD47 receptor, in various tumour indications with a high medical need. Other promising programmes targeting the extracellular matrix are also in development.

France

Grand Est

Biotech

Targeted therapy

Biotech - Pre-IND/Pre-CTA

Lauréat

iLAB, iNov, EIC laureate

Apmonia Therapeutics

Specializing in the development of innovative cell therapies - chimeric antigen receptor T cells (CAR-T), T cell receptor T cells (TCR-T) and tumor-infiltrating lymphocytes (TIL) - for the treatment of cancer.

Singapore

Biotech

Cell & Gene therapy

Biotech - Phase 2

BioSyngen

Develops drugs targeting the mutated DNA that causes serious diseases, with a particular focus on paediatric tumours. Using its proprietary MyGenera™ platform, the company rapidly identifies and designs ultra-specific therapies tailored to each patient. This revolutionary approach opens up new prospects for treating hitherto incurable pathologies.

Italy

Bologna

Biotech

Cell & Gene therapy

Biotech - Pre-IND/Pre-CTA

Biogenera

Blue Bees is developing first-in-class immunotherapies based on a breakthrough technology exploiting dual targeting of cell receptors coupled to heparan sulphate proteoglycans (HSPGs). This innovative approach aims to boost the anti-tumour immune response and open up new therapeutic prospects.

France

Île-de-France

Biotech

Immunotherapy

Biotech - Pre-IND/Pre-CTA

Blue Bees Therapeutics

Develops next-generation allogeneic immunotherapies to prevent cancer recurrence, the main challenge in solid tumours. Using its patented technology platform, the company designs first-in-class therapeutic vaccines targeting tumour antigens and educating the immune system to overcome tumour resistance. Its lead candidate, a proteomic immunotherapy, targets colorectal cancer, the second most common cause of cancer deaths worldwide.

France

Auvergne-Rhône-Alpes

Biotech

Immunotherapy

Biotech - Pre-IND/Pre-CTA

Lauréat

iLAB

Brenus Pharma

Develops a new generation of cellular therapies in oncology by combining modified Fc ligands with non-genetically modified effector cells. Leverages the patented Pin™ platform to design modular combinations of antibodies and cells, optimising targeting precision while improving treatment efficacy and tolerability.

France

Occitanie

Biotech

Cell & Gene therapy

Biotech - Pre-IND/Pre-CTA

CYTEA BIO

Aims to develop a platform for the genetic engineering of autologous monocytes to boost anti-tumour immunity, with an approach aimed at designing personalized cell therapies and enabling the rapid and effective reinfusion of modified monocytes to fight cancer.

France

Île-de-France

Biotech

Cell & Gene therapy

Biotech - Discovery

CedraTherapeutics

Is developing a real-time surgical guidance technology combining laser, mass spectrometry and artificial intelligence. Its innovative system enables precise identification of tumour tissue and surgical margins, optimising tumour removal while preserving healthy tissue. The aim of this approach is to reduce the risk of relapse and improve the outcome of oncology operations.

France

Hauts de France

Medtech

Medtech - Laboratory PoC

Lauréat

iLAB

Celeos

Focused on the manufacturing of breakthrough cell therapies. Their bioreactor with unique properties (controlled shear forces, homogeneity, easy scale-up, etc.) meets the challenges of expanding induced pluripotent stem (iPS) cells.

France

Provence-Alpes-Côte d'Azur

Medtech

Cell & Gene therapy

Medtech - Development

Cellura

Cherry Biotech markets a technological platform integrating cellular engineering, microfluidics, artificial intelligence and advanced imaging to recreate 3D human models (organs on a chip). Its aim is to anticipate the impact of treatments on the body, particularly for orphan diseases, cancer and bacterial resistance. Its patented CUBIX technology makes it possible to grow complex, vascularized tissue models, offering an ethical and innovative alternative to animal testing, while integrating into current industrial workflows.

France

Île-de-France

Medtech

TechBio

Medtech – Market

Lauréat

iLAB, EIC laureate

Cherry Biotech

Is developing a therapeutic target discovery platform based on a proprietary clinical and multiomics database of patients who have survived aggressive cancers. By combining comparative multiomics analyses with artificial intelligence and computational modelling, Cure51 identifies unique biological signatures to design new targeted therapies and open up new perspectives in oncology.

France

Île-de-France

Medtech

TechBio

Medtech - Development

Lauréat

iLAB

Cure51

Is developing an AI-based tool to predict patient response to immunotherapies and optimise therapeutic decisions. By combining genomics, imaging and clinical data, its platform offers personalized recommendations, improving the effectiveness of treatments while reducing adverse effects and costs.

Londres

Medtech

DM/DiV

Medtech - Development

Curenetics

Develops a SaaS platform combining generative AI and multi-omics data to create digital twins of cells, accelerating cellular engineering and drug discovery. Using deep learning algorithms, this technology enables in silico simulations to identify new therapeutic targets. A current project focuses on brain stem infiltrating glioma (BSIG), a rare paediatric cancer.

France

Île-de-France

Medtech

TechBio

Medtech - Development

DeepLife

A spin-off from the Vaccine Research Institute, EnnoDC is a clinical-stage immunotherapy company pioneering antibody-mediated vaccines (AMVs) for cancers and infectious diseases. By precisely delivering the antigen of interest to dendritic cells, AMVs maximize CD8, CD4 T, and B cell responses. With no collateral toxicity and fully scalable, its candidates fit into a unique plug-and-play platform, ensuring targeted and long-lasting immunity.A spin-off from the Vaccine Research Institute, EnnoDC is a clinical-stage immunotherapy company pioneering antibody-mediated vaccines (AMVs) against cancers and infectious diseases. By precisely delivering the antigen of interest to dendritic cells, AMVs maximise CD8, CD4 T and B responses. With no collateral toxicity and fully scalable, these candidates can be integrated into a unique plug & play platform, guaranteeing targeted, long-lasting immunity.

France

Île-de-France

Biotech

Immunotherapy

Biotech - Phase 1/2a

EnnoDC

Designs immunotherapies based on the identification of unconventional tumour antigens derived from human endogenous retroviruses (HERVs). Using an approach combining artificial intelligence, proteomics and immunology, it is developing therapeutic vaccines and cell-based therapies to target cold tumours. Its lead candidate is a universal vaccine against triple-negative breast cancer and ovarian cancer.

France

Auvergne-Rhône-Alpes

Biotech

Immunotherapy

Biotech - Pre-IND/Pre-CTA

Lauréat

iLAB, EIC laureate

ErVimmune

Is developing the Oncobax® AK biotherapy, which uses immunogenic commensal bacteria to enhance the efficacy of immune checkpoint inhibitors. This approach is based on the modulation of intestinal microbiota to improve the response to immunotherapies in the treatment of kidney cancer and non-small cell lung cancer.

France

Île-de-France

Biotech

Microbial-based therapy

Biotech - Phase 1

EverImmune

Abbelight's project to develop a liquid biopsy diagnostic technology combining super-resolution microscopy, extracellular vesicles and artificial intelligence. This approach improves the detection and analysis of circulating biomarkers, offering greater precision for the early diagnosis and monitoring of diseases, particularly in oncology. By integrating these advances, the solution optimises precision medicine and opens up new prospects for more targeted and effective treatments.

France

Île-de-France

Medtech

DM/DiV

Medtech - Development

Evolve

Designs highly sensitive technologies for the analysis of extracellular vesicles, opening up new perspectives in liquid biopsy. Its diagnostic platforms enable the early detection of cancer, particularly ovarian cancer, by identifying protein markers with unrivalled precision. This innovative approach improves screening, tumour monitoring and anticipation of relapse.

France

Île-de-France

Medtech

DM/DiV

Medtech - Development

Exosome Analytics

Develops a CE-marked microbiome-based in vitro diagnostic test to predict response to immune checkpoint inhibitors.

France

Île-de-France

Medtech

DM/DiV

Medtech - Development

GMT Science

Develops, manufactures and markets innovative diagnostic tests based on next-generation sequencing to better characterize non-Hodgkin's lymphomas and sarcomas. These patented tests offer rapid, reliable diagnosis without the need for additional equipment, making them easier to adopt in routine clinical practice and optimising patient care.

France

Normandie

Medtech

DM/DiV

Medtech – Market

Genexpath

Is developing a microwave ablation platform incorporating a flexible catheter equipped with a temperature sensor for real-time monitoring of tissue ablation. This minimally invasive technology offers surgeons a safer and more precise solution for the early treatment of lung cancer, by directly targeting lesions without recourse to major surgery.

France

Île-de-France

Medtech

Medtech - Development

HEPTA Medical

Hephaistos is developing innate immunity modulators capable of transforming immuno-resistant ‘cold’ tumours into ‘hot’ tumours by modifying their micro-tumour environment. The company has obtained preclinical proof-of-concept for the first systemic TLR4 activator with efficacy against primary tumours and metastases, alone and in combination. The HEPHA-440 drug candidate has received orphan drug designation for the treatment of osteosarcoma and is expected to enter the clinic by 2027.

France

Île-de-France

Biotech

Immunotherapy

Biotech - Pre-IND/Pre-CTA

Lauréat

iLAB, iNov, EIC laureate, RHU

Hephaistos Pharma

Has designed a robot dedicated to flexible interventional endoscopy for minimally invasive operations inside the patient. By bringing surgical instruments to the end of the endoscope, this technology democratizes complex gastroenterology operations.

France

Île-de-France

Medtech

Medtech - Development

INEN Robotics

Building on major scientific advances in the regulation of endoplasmic reticulum stress, this future start-up aims to propose an innovative drug candidate to meet major medical needs in glioblastoma and brain metastases.

France

Bretagne

Biotech

Targeted therapy

Biotech - Discovery

IRE-1

Aims to develop imaging biomarker signatures to predict prognosis and response to immunotherapy. By combining radiomics and artificial intelligence, this future start-up aims to transform the analysis of medical images into a powerful predictive tool, enabling greater personalisation of oncology treatments.

France

Île-de-France

Medtech

Medtech - Laboratory PoC

IRIS

Is developing a next-generation medical imaging technology based on QUTE-CE MRI, which provides high-resolution vascular biomarkers. This non-invasive approach enables the precise assessment of the structure and function of small blood vessels throughout the body, providing clinicians and researchers with new tools for the early detection and characterization of complex diseases, including cancer.

USA

Florida

Medtech

Medtech - Development

Imaginostics

Specializing in the discovery of new drug candidates using its in silico drug design technology platforms, InFocus is developing a pipeline of small molecules capable of modulating the translation of oncogenic mRNAs. Its drug candidates, with excellent brain penetration properties, target central nervous system cancers such as glioblastoma and brain metastases, opening up new prospects for treating previously inaccessible targets.

France

Île-de-France

Biotech

Targeted therapy

Biotech - Lead optimization

InFocus

Builds on a platform for the discovery of new therapeutic candidates exploiting non-oncogenic addiction mechanisms in tumour cells to develop therapies targeting signalling pathways essential to tumour cell survival, with a focus on haematological cancers and melanoma. Its most advanced candidate, JRT39, is a first-in-class molecule derived from the AAC-11 protein, combining the specificity of antibodies and the cellular penetration of small molecules to overcome resistance to existing treatments.

France

Île-de-France

Biotech

Targeted therapy

Biotech - Lead optimization

Lauréat

iLAB, iNov

Jalon Therapeutics

Commercialises an intelligent and intuitive search platform for oncology clinical trials, facilitating patient access to new therapeutic options and helping doctors to quickly identify suitable studies thanks to AI.

France

Île-de-France

Medtech

e-health

Medtech – Market

Klineo

Aims to develop and market an innovative marker detection and quantification technology for diagnosing cancers at an early stage.

France

Bretagne

Medtech

DM/DiV

Medtech - Laboratory PoC

Kwan Tek

Has developed an innovative mammography technology from a CNRS laboratory, enabling early detection of breast cancer by visualizing small masses in dense tissue.

France

Nouvelle Aquitaine

Medtech

Medtech - Laboratory PoC

LetSee Imaging

MS Insights, a company specializing in genomics and bioinformatics, is developing innovative diagnostic solutions for the analysis of microsatellite instability (MSI), a key biomarker in oncology. Using tools based on high-throughput sequencing (NGS) data, the company provides valuable information on microsatellite variations, optimising diagnosis and therapeutic guidance, particularly for immune checkpoint inhibitors. Its flagship product, MSIcare, aims to become a benchmark in diagnosis, prognosis and theranostics.

France

Auvergne-Rhône-Alpes

Medtech

DM/DiV

Medtech - Development

Lauréat

iLAB

MSInsight

Is developing a new generation of immunoconjugates targeting CD56+ cancers. Its first candidate is an ADC, designed to deliver a cytotoxic load directly to tumour cells, with a focus on small cell lung cancer and Merkel cell carcinoma.

France

Centre Val de Loire

Biotech

Targeted therapy

Biotech - Lead optimization

McSAF Inside Oncology

Minos is developing a cell analysis technology combining multi-omics and phenotypic study at the scale of the single cell and at high throughput, making it possible to simultaneously examine gene expression and the functional characteristics of cells, providing a comprehensive view of their diversity and dynamics.

France

Île-de-France

Medtech

TechBio

Medtech - Development

Minos Biosciences

Develops functionalized gold nanoparticles to deliver innovative dual therapy for glioblastoma, combining chemotherapy and radiotherapy in a smart nanosphere. This synergistic approach boosts treatment efficacy while reducing side effects, thanks to precise targeting of solid tumorstumours.adiothérapie dans une nanosphère intelligente. Cette approche synergique augmente l’efficacité du traitement tout en réduisant les effets secondaires grâce à un ciblage précis des tumeurs solides.

France

Bourgogne Franche Comté

Biotech

Nanomedecine

Biotech - Lead optimization

ORINOVA

Develops degradable polymer hydrogels for controlled release of active ingredients. Its biocompatible microspheres enable targeted, adjustable delivery. An oncology application is under development for the treatment of liver cancer, with prospects for tumour embolization and pain management.

France

Île-de-France

Medtech

Medtech - Development

Occlugel

Develops personalized cancer immunotherapy, combining artificial intelligence and synthetic DNA technology to design customized vaccines. Its platform identifies and encodes tumor-specific neoantigens within optimized DNA, triggering a targeted, long-lasting immune response. Its precision medicine approach opens up new prospects for aggressive cancers, notably melanoma, colorectal cancer and breast cancer.

France

Grand Est

Biotech

Immunotherapy

Biotech - Pre-IND/Pre-CTA

Odimma Therapeutics

Develops next-generation immunotherapies for the treatment of cancer. Its clinical platform is based on innovative approaches aimed at boosting the anti-tumour immune response and overcoming resistance to current treatments.

France

Île-de-France

Biotech

Immunotherapy

Biotech - Phase 1/2a

Onconex-Remunity Therapeutics

Oncovita is an Institut Pasteur spin-off developing immuno-virotherapies for solid cancers, based on a genetically modified measles vaccine virus. Its lead candidate, MVdeltaC, is an oncolytic virus capable of inducing immunogenic cell death, and has shown promising preclinical results in numerous models, including immunocompetent mice. This virus specifically targets tumour cells overexpressing the CD46 receptor and induces a durable anti-tumour immune response.

France

Île-de-France

Biotech

Immuno virotherapy

Biotech - Pre-IND/Pre-CTA

Oncovita

Leverages single-cell technologies and artificial intelligence to establish high-resolution omic profiles for precision medicine.

France

Île-de-France

Medtech

TechBio

Medtech - Development

One Biosciences

Operates a technology platform combining patient tumour avatars with real clinical data and cutting-edge biology. This artificial intelligence-powered approach accelerates the identification of therapeutic targets and the development of treatments, while optimizing the recruitment of responder patients.

France

Île-de-France

Medtech

TechBio

Medtech - Development

Lauréat

iLAB

Orakl Oncology

Develops monoclonal antibodies neutralizing ACBP/DBI, the level of which is very high in various pathologies, notably cancers, and which is responsible for the feedback inhibition of cellular autophagy.

Suisse

Lausanne

Biotech

Targeted therapy

Biotech - Discovery

Osasuna

Creation of a start-up dedicated to the development of a drug candidate for the treatment of pancreatic cancer, based on the discovery of a new therapeutic target.

France

Provence-Alpes-Côte d'Azur

Biotech

Targeted therapy

Biotech - Discovery

PANCA

Develops innovative peptides as targeted therapies in oncology. Its lead drug candidate, PEP-010, is a pro-apoptotic peptide that has demonstrated anti-tumoranti-tumour efficacy in several preclinical models, as well as good tolerability and encouraging early signals of anti-tumoranti-tumour activity in Phase Ia clinical trials. The Phase Ib trial is currently underway, focusing on platinum-resistant ovarian cancer and pancreatic adenocarcinoma.

France

Île-de-France

Biotech

Targeted therapy

Biotech - Phase 1b

PEP Therapy

Pegascy specializes in repositioning oncology compounds that have been discontinued after Phase 1, by exploring their therapeutic potential in various indications. The company is currently developing istiratumab, a bispecific Igfr/Her3 antibody, in Phase 2 for Ewing's sarcoma and endometrial cancer. Following the success of PegaOne, which will be sold to Centessa in 2021, PEGASCY is preparing the launch of PegaTwo, targeting pediatric and female cancers.

France

Île-de-France

Biotech

Targeted therapy

Biotech - Phase 2

Pegascy

Develops first-in-class peptides that have demonstrated preclinical efficacy in several solid and liquid cancers, notably chronic lymphocytic leukemia, with no observed toxicity. Thanks to an innovative platform combining biology, chemistry and artificial intelligence, peptides are designed to specifically target CD47, enabling tumour cells to be destroyed while sparing healthy cells.

France

Île-de-France

Biotech

Targeted therapy

Biotech - Lead optimization

Lauréat

iLAB

PepKon

Develops an allogeneic suicide gene therapy (MTI) to treat liver cancer. The therapy uses allogeneic mesenchymal stem cells transfected with a cyclophosphamide-activated suicide gene (CPA), enhancing tumour sensitivity to chemotherapy. The mechanism enables tumour destruction while generating an immune response that prevents tumour recurrence. Proof of concept carried out in vitro and in vivo.

France

Île-de-France

Biotech

Cell & Gene therapy

Biotech - Lead optimization

Persea

Develops PT-112, an innovative anti-cancer agent inducing immunogenic cell death. Targeting ribosome biogenesis, this drug candidate promotes an anti-tumour immune response by activating cytotoxic T lymphocytes. PT-112 has shown promising results in combining direct tumour treatment with stimulation of anti-cancer immunity, paving the way for innovative therapeutic solutions against solid and haematological cancers.

USA

New York

Biotech

Targeted therapy

Biotech - Phase 2

Promontory Therapeutics

Is marketing a new generation of cancer screening tests, particularly for prostate cancer, based on a personalized “in silico” approach. By combining in-vitro biological data with the patient's personal information, these accessible, non-invasive tests enable a more accurate risk assessment and referral to complementary examinations, such as ultrasound, for an early, personalized diagnosis.

France

Grand Est

Medtech

DM/DiV

Medtech – Market

Prostperia

France

Île-de-France

Biotech

Cell & Gene therapy

Biotech - Lead optimization

Quintessence Biotech

Develops an artificial intelligence solution to improve radiological analysis, enabling the detection of tumours, the monitoring of their evolution and the measurement of RECIST criteria. Thanks to a multimodal model, this technology can integrate and analyze different types of data, such as images and text, facilitating access to imaging biomarkers for more accurate diagnoses.

France

Île-de-France

Medtech

Medtech - Development

Lauréat

EIC laureate, iLAB

Raidium

Designs first-in-class BCRP inhibitors to restore the efficacy of anti-cancer treatments and combat multi-drug resistance. Thanks to its leading molecule ValOMé, a selective and non-toxic inhibitor, the start-up aims to improve the response of patients in therapeutic failure by combining its action with various chemotherapies, targeted therapies, hormone therapies and immunotherapies.

France

Auvergne-Rhône-Alpes

Biotech

Targeted therapy

Biotech - Lead optimization

Lauréat

iLAB

ReACT Therapeutics

Is developing an innovative platform of biocompatible, biodegradable polysaccharide-based hydrocolloid gels for the controlled subcutaneous release of therapeutic antibodies and ADCs. This approach aims to make biological cancer treatments more accessible by facilitating rapid, convenient subcutaneous administration for patients and hospitals.

France

Grand Est

Biotech

Targeted therapy

Biotech - Lead optimization

Recobia Tx

Develops a simple, effective blood test for the early detection of multiple types of cancer. By exploiting exosome biology, this liquid biopsy technology enables tumours to be identified at a very early stage, even in asymptomatic patients. The aim is to make this detection available worldwide, using standard laboratory techniques and at an affordable cost.

Cardiff

Medtech

DM/DiV

Medtech - Development

Rivela Diagnostics

Develops miniaturized microrobots for neurosurgery, enabling biopsies to be taken, treatments to be delivered and post-operative follow-up to be carried out in hard-to-reach areas of the body. Thanks to advanced robotics and artificial intelligence technologies, these microrobots offer enhanced precision and can be adapted to a variety of medical applications for more effective, less invasive treatments.

France

Île-de-France

Medtech

Medtech - Development

Lauréat

EIC laureate

Robeauté

Develops a diagnostic probe for fluorescence-guided surgery, aimed at detecting tumours invisible to the naked eye and preventing relapse of abdominal cancers. Targeting peritoneal metastases from colorectal, gastric, ovarian and pancreatic cancers, this technology enables early and accurate detection of lesions, whether visible during open or minimally invasive surgery, helping to improve surgical outcomes and reduce the risk of recurrence.

France

Occitanie

Biotech

Fluorescent-probe for targeted surgery

Biotech - Lead optimization

See2Cure

Develops a targeted antigen delivery system using plant-derived nanoparticles, enabling rapid, cost-effective production. The technology is based on modular particles capable of carrying various active ingredients (proteins, peptides, mRNAs) and specifically targeting immune cells, notably in therapeutic oncology vaccines. This approach optimizes the activation of immune responses against tumours, with simple, human pathogen-free production and high stability for practical use.

France

Grand Est

Biotech

Immunotherapy

Biotech - Discovery

Serendip innovations

Markets portable products for liquid biopsy of circulating tumour cells (CTCs), to make this procedure standardized, accessible and used in routine clinical practice. This liquid biopsy approach offers better representativeness of solid tumours by enabling real-time monitoring, while personalizing care. These microfiltration devices isolate CTCs directly from whole blood, without the need for pre-analytical steps, facilitating diagnosis, monitoring and personalized treatment.

France

Occitanie

Medtech

DM/DiV

Medtech – Market

Lauréat

iLAB

SmartCatch

Develops first-in-class drug targeting cGAS and using mRNA technology to stimulate innate immunity. By activating the STING pathway, this approach boosts the immune response against cancers and other pathologies, particularly in patients refractory to conventional treatments. Using virus-like particles (VLPs), this technology stimulates cytokine production and boosts immune cell response.

France

Île-de-France

Biotech

Immunotherapy

Biotech - Lead optimization

Lauréat

iLAB

Stimunity

Combines the Warburg effect and click chemistry to improve addressing of various anti-tumour molecules (small molecules, SiRNAs, antibodies, etc.) and reduce their side effects. Thanks to the specific uptake by tumour cells of patented modified sugars fitted with chemical hooks, this method enables therapeutic agents to be concentrated locally via a “click” chemical reaction (Nobel Prize 2022) between the cell hooks and the charge carriers.

France

Provence-Alpes-Côte d'Azur

Biotech

Targeted therapy

Biotech - Lead optimization

TheraOnco

Is developing a revolutionary technology using non-invasive focused ultrasound to enhance drug delivery to the brain. By specifically targeting the blood-brain barrier (BBB), this approach makes it possible to cross this protective barrier and deliver therapeutic treatments to targeted areas of the brain, as in the case of primary tumours or brain metastases.

France

Île-de-France

Medtech

Medtech - Development

Lauréat

iLAB

TheraSonic

Exploits the natural properties of the sortilin protein to develop therapeutic solutions targeting EGFR-positive tumours. Their first innovation is a sortilin-derived peptide designed to treat lung adenocarcinoma.

France

Nouvelle Aquitaine

Biotech

Targeted therapy

Biotech - Lead optimization

Yomi Pharma

Has patented a diagnostic technology based on multi-dosing of circulating miRNAs by electrochemistry in microfluidics, combining magnetic hyperthermia and electrochemical detection for rapid, sensitive and multiplexed analysis, facilitating early cancer detection with increased accuracy and reduced cost.

France

Île-de-France

Medtech

DM/DiV

Medtech - Development

e-miRgency